<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00886496</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000523819</org_study_id>
    <secondary_id>ENZON-EZN-2232-03</secondary_id>
    <secondary_id>NCI-07-C-0027</secondary_id>
    <nct_id>NCT00886496</nct_id>
  </id_info>
  <brief_title>Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia</brief_title>
  <official_title>A Multi-Center Study of the Safety, Tolerability, Pharmacokinetics and Dose Escalation of Intravenous Recombinant Human Mannose-Binding-Lectin (rhMBL) in MBL Deficient Pediatric Hematology/Oncology Patients With Fever and Neutropenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enzon Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Enzon Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      RATIONALE: Recombinant human mannose-binding lectin (MBL) may be effective in preventing&#xD;
      infection in young patients with fever and neutropenia receiving chemotherapy for blood&#xD;
      disease or cancer.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of recombinant human&#xD;
      mannose-binding lectin in treating young patients with MBL deficiency and fever and&#xD;
      neutropenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety and tolerability of recombinant human mannose-binding lectin (MBL)&#xD;
           in pediatric patients with MBL deficiency and fever and neutropenia who are undergoing&#xD;
           cytotoxic chemotherapy for hematological/oncological disease.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the pharmacodynamic effect of this drug in these patients.&#xD;
&#xD;
        -  Determine nonspecific activation of complement by in vivo determination of C3d&#xD;
           complement activation in patients treated with this drug.&#xD;
&#xD;
        -  Determine the ex-vivo activity of recombinant MBL in opsonization capacity of patients'&#xD;
           sera to yeast and bacteria.&#xD;
&#xD;
        -  Determine immunogenicity of this drug in these patients.&#xD;
&#xD;
        -  Determine the incidence and duration of fever and breakthrough infections in patients&#xD;
           treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a non-randomized, multicenter, open-label, prospective, cohort study.&#xD;
      Patients are assigned to 1 of 2 treatment groups.&#xD;
&#xD;
        -  Group I: Patients receive low-dose recombinant human mannose-binding lectin (MBL) IV&#xD;
           over 1 hour within 72 hours of onset of fever and neutropenia.&#xD;
&#xD;
        -  Group II: Patients receive high-dose recombinant human MBL IV over 1 hour within 72&#xD;
           hours of onset of fever and neutropenia.&#xD;
&#xD;
      Patients undergo blood collection periodically during study for pharmacokinetic,&#xD;
      pharmacodynamic, MBL immunogenicity, and opsonization/phagocytosis studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 30 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 48 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No participants enrolled. IND withdrawn.&#xD;
  </why_stopped>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy</measure>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Fever, Sweats, and Hot Flashes</condition>
  <condition>Infection</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Neutropenia</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant human mannose-binding lectin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Undergoing cytologic chemotherapy for hematological/oncological disease&#xD;
&#xD;
          -  Must meet all of the following criteria:&#xD;
&#xD;
               -  Documented mannose-binding lectin (MBL) levels &lt; 300 ng/mm³ within the past week&#xD;
&#xD;
               -  Fever (oral temperature &gt; 100.4° F)&#xD;
&#xD;
               -  Neutropenia, defined as absolute neutrophil count ≤ 1,000/mm³ with the&#xD;
                  anticipation that the counts will fall below 500/mm^3&#xD;
&#xD;
               -  Receiving broad spectrum antibiotic therapy for fever and neutropenia&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  No serious illness, in the opinion of the principal investigator, that would preclude&#xD;
             study compliance&#xD;
&#xD;
          -  No known allergic reactions to mannose-binding lectin or other human plasma products&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier method contraception during and for ≥ 30&#xD;
             days after completion of study treatment&#xD;
&#xD;
          -  AST and ALT ≤ 5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 2.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance &gt; 60 mL/min OR creatinine based on age as follows:&#xD;
&#xD;
               -  No more than 0.8 mg/dL (for patients 5 years of age and under)&#xD;
&#xD;
               -  No more than 1.0 mg/dL (for patients 6-9 years of age)&#xD;
&#xD;
               -  No more than 1.2 mg/dL (for patients 10-12 years of age)&#xD;
&#xD;
               -  No more than 1.4 mg/dL (for patients over 13 years of age [female])&#xD;
&#xD;
               -  No more than 1.5 mg/dL (for patients 13-15 years of age [male])&#xD;
&#xD;
               -  No more than 1.7 mg/dL (for patients of 16 years of age [male])&#xD;
&#xD;
          -  No poor venous access that would preclude IV drug delivery or multiple blood draws&#xD;
&#xD;
          -  Patients on hemodialysis must be able to tolerate IV fluid on non-dialysis days&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 30 days since prior investigational agents&#xD;
&#xD;
               -  Investigational use of an FDA-approved drug allowed&#xD;
&#xD;
          -  No concurrent preparative regimen for a bone marrow or hematopoietic stem cell&#xD;
             transplantation&#xD;
&#xD;
          -  No concurrent participation in another clinical trial with an investigational agent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas J. Walsh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <study_first_submitted>April 21, 2009</study_first_submitted>
  <study_first_submitted_qc>April 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2009</study_first_posted>
  <last_update_submitted>June 19, 2012</last_update_submitted>
  <last_update_submitted_qc>June 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2012</last_update_posted>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>fever, sweats, and hot flashes</keyword>
  <keyword>neutropenia</keyword>
  <keyword>infection</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage I and II childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage I childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage II childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage III and IV childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage III childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>stage I and II childhood lymphoblastic lymphoma</keyword>
  <keyword>stage I childhood lymphoblastic lymphoma</keyword>
  <keyword>stage II childhood lymphoblastic lymphoma</keyword>
  <keyword>stage III and IV childhood lymphoblastic lymphoma</keyword>
  <keyword>stage III childhood lymphoblastic lymphoma</keyword>
  <keyword>stage IV childhood lymphoblastic lymphoma</keyword>
  <keyword>childhood Burkitt lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>stage I childhood Hodgkin lymphoma</keyword>
  <keyword>stage II childhood Hodgkin lymphoma</keyword>
  <keyword>stage III childhood Hodgkin lymphoma</keyword>
  <keyword>stage IV childhood Hodgkin lymphoma</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>untreated childhood acute myeloid leukemia and other myeloid malignancies</keyword>
  <keyword>childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>childhood diffuse large cell lymphoma</keyword>
  <keyword>childhood immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>stage I childhood large cell lymphoma</keyword>
  <keyword>stage II childhood large cell lymphoma</keyword>
  <keyword>stage III and IV childhood large cell lymphoma</keyword>
  <keyword>stage III childhood large cell lymphoma</keyword>
  <keyword>stage IV childhood large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lectins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

